½ÃÀ庸°í¼­
»óǰÄÚµå
1773145

Medical AffairsÀÇ ÆòÆÇ(¹Ì±¹) : °Ç¼±¼º °üÀý¿°

Medical Affairs Reputations (US) - Psoriatic Arthritis

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: FirstWord Group | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

ÀÌ º¸°í¼­´Â ¹Ì±¹ ·ù¸¶Æ¼½º Àü¹®ÀǵéÀÇ Á¤·®Àû Çǵå¹éÀ» ¹ÙÅÁÀ¸·Î °Ç¼±¼º °üÀý¿° Ä¡·á¸¦ Áö¿øÇÏ´Â ¸ÞµðÄà ¾îÆä¾îÁî ÆÀÀÇ ¼º°ú¿Í ÆòÆÇÀ» Á¶»çÇß½À´Ï´Ù. ÀÌ º¸°í¼­´Â ÀÇ»çµéÀÌ ¸ÞµðÄà ¾îÆä¾îÁî Àü¹®°¡¿Í ¾î¶»°Ô ±³·ùÇÏ´ÂÁö, ÀÇ»çµéÀÌ °¡Àå °¡Ä¡ ÀÖ´Ù°í »ý°¢ÇÏ´Â ¼­ºñ½º´Â ¹«¾ùÀÎÁö, Á¦Ç°º° ÇöÀç Áö¿ø¿¡ ¾ó¸¶³ª ¸¸Á·ÇÏ´ÂÁö µîÀ» Á¶»çÇß½À´Ï´Ù. ¶ÇÇÑ, ¼±È£Çϴ ä³Î°ú Âü¿© ºóµµ, ÀÇ»çÀÇ ¿ä±¸°¡ ÃæÁ·µÇÁö ¾Ê´Â ¿µ¿ª, ÁÖ¿ä ¼º°ú ¿µ¿ª¿¡¼­ °¢ ÆÀÀÇ °æÀï»ç¿ÍÀÇ ºñ±³¸¦ °­Á¶Çϰí ÀÖ½À´Ï´Ù.

ÁÖ¿ä Áú¹®

  • ÀÇ»ç´Â ÀÇ·áÁøµéÀÌ ¸ÞµðÄà ¾îÆä¾î ÆÀ°ú ¾ó¸¶³ª ÀÚÁÖ ±³·ùÇϰí ÀÖÀ¸¸ç, ±× ºóµµ´Â Áõ°¡Çϰí Àִ°¡, °¨¼ÒÇϰí Àִ°¡?
  • ÇöÀç ÀÇ»çµéÀº ¸ÞµðÄà ¾îÆä¾î ÆÀÀÌ Á¦°øÇÏ´Â ¼­ºñ½º¸¦ ¾î¶² ÇüÅ·ΠÀÌ¿ëÇϰí Àִ°¡?
  • ¸ÞµðÄà ¾îÆä¾î½ºÀÇ Áö¿ø Áß Àǻ翡°Ô °¡Àå Áß¿äÇÑ °ÍÀº ¹«¾ùÀ̸ç, Á¦°øµÇ´Â Áö¿ø¿¡ ¾ó¸¶³ª ¸¸Á·Çϴ°¡?
  • ÀÇ»ç¿Í ¸ÞµðÄà ¾îÆä¾î ÆÀ °£ÀÇ ¾î¶² À¯ÇüÀÇ ±³·ù¸¦ ¼±È£Çϸç, ±× ºóµµ´Â ¾î´À Á¤µµ°¡ ¹Ù¶÷Á÷ÇÏ´Ù°í »ý°¢Çϴ°¡?
  • ¸ÞµðÄà ¾îÆä¾î ÆÀÀº ÀÇ»çÀÇ ¿ä±¸¿¡ ¾ó¸¶³ª Àß ´ëÀÀÇϰí Àִ°¡?
  • ¸ÞµðÄà ¾îÆä¾î ÆÀÀº ƯÁ¤ ºê·£µå¿¡¼­ ¸ñǥġ¸¦ ¹Øµ¹°í Àִ°¡, ¾Æ´Ï¸é Ãʰú ´Þ¼ºÇϰí Àִ°¡?
  • ¾ÕÀ¸·Î ÀÇ»çÀÇ ¿ä±¸¸¦ ÃæÁ·½Ã۱â À§ÇØ ÀÇ·á ¾÷¹« ¼­ºñ½º¸¦ ¾î¶»°Ô °³¼±ÇÒ ¼ö ÀÖÀ»±î?
  • °æÀï»çÀÇ ¸ÞµðÄà ¾îÆä¾î ÆÀÀÌ °¡Àå ¾àÇÑ ºÐ¾ß¿Í °¡Àå °­ÇÑ ºÐ¾ß´Â ¹«¾ùÀΰ¡?

ÁÖ¿ä ºê·£µå

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

Á¶»ç ¹æ¹ý:

FirstView º¸°í¼­´Â 300¸¸ ¸í ÀÌ»óÀÇ Àǻ簡 È®ÀÎµÈ ¼¼°è ÃÖ´ë ±Ô¸ðÀÇ ÀÇ»ç µð·ºÅ丮ÀÎ LiMATMÀ» ÅëÇØ ¼±º°µÈ ÀÇ»çµéÀ» ´ë»óÀ¸·Î ½Ç½ÃÇÑ Á¤·®Àû ¼³¹®Á¶»ç¸¦ ÅëÇØ °³¹ßµÇ¾ú½À´Ï´Ù. °¢ ÀÇ»ç´Â ¾ö°ÝÇÑ ½É»ç ±âÁØ¿¡ µû¶ó ½ÅÁßÇÏ°Ô ¼±Á¤µÇ¾î ¼öÁýµÈ ÀλçÀÌÆ®°¡ ÀûÀýÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖÀ¸¸ç, ÃÖ°í ¼öÁØÀÇ ÀÇ·á Àü¹®°¡µéÀÇ ÁøÁ¤ÇÑ °¨Á¤°ú °æÇèÀ» ¹Ý¿µÇϰí ÀÖ´ÂÁö È®ÀÎÇÕ´Ï´Ù. FirstView º¸°í¼­´Â LiMATMÀÇ ¹æ´ëÇÑ µµ´Þ ¹üÀ§¿Í Á¤È®¼ºÀ» Ȱ¿ëÇÏ¿© Àü·«Àû °èȹ ¼ö¸³¿¡ µµ¿òÀÌ µÇ´Â µ¶º¸ÀûÀÎ µ¥ÀÌÅÍ ±â¹Ý ÅëÂû·ÂÀ» Á¦°øÇϰí, ºü¸£°Ô º¯È­ÇÏ´Â ÀÇ·á ȯ°æ ¼Ó¿¡¼­ ÇÑ ¹ß ¾Õ¼­ ³ª°¥ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

´ç»ç º¸°í¼­ÀÇ Æ¯Â¡

FirstWord Reports´Â Á¦¾à ºÎ¹®¿¡ ƯȭµÈ ½Å·ÚÇÒ ¼ö ÀÖ´Â ¾÷°è ¸®´õ·Î¼­ ¹ÙÀÌ¿ÀÁ¦¾à Àü¹®°¡¿Í ÀÇ»ç°áÁ¤±ÇÀÚ¸¦ À§ÇÑ »ó¼¼ÇÏ°í ½Ç¿ëÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ´ç»çÀÇ ½ÉÃþÀûÀÎ ¾÷°è Áö½ÄÀº °í°´ÀÌ »õ·Î¿î Æ®·»µå¸¦ ÆÄ¾ÇÇÏ°í º¹ÀâÇÑ ¹®Á¦¸¦ È¿°úÀûÀ¸·Î ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÇ´Â ÀûÀýÇÏ°í °¡Ä¡ ÀÖ´Â ÅëÂû·ÂÀ» Á¦°øÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù. ±¤¹üÀ§ÇÑ Á¶»ç¿Í ÃÖ°íÀÇ Àü¹®°¡ ¹× KOLÀÇ µ¶¸³ÀûÀÌ°í °øÁ¤ÇÑ ÅëÂû·ÂÀ» ¹ÙÅÁÀ¸·Î ÇÑ ´ç»çÀÇ º¸°í¼­´Â °í°´ÀÌ ÇÊ¿ä·Î ÇÏ´Â Á¤È®¼º°ú ½Å·Ú¼ºÀ» Á¦°øÇÕ´Ï´Ù. ´Ù¸¥ °÷¿¡¼­´Â ¾òÀ» ¼ö ¾ø´Â ÀÎÅͺä¿Í µ¥ÀÌÅÍ¿¡ ´ëÇÑ µ¶Á¡Àû Á¢±Ù, Áö¼ÓÀûÀÎ ½ÃÀå ¸ð´ÏÅ͸µÀ» ÅëÇØ ½ÃÀå ¿ªÇп¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù.40À»KOL ÀλçÀÌÆ®·Â°ú Á¤·®Àû ÀÇ»ç Á¶»ç¸¦ Æ÷ÇÔÇÑ ÀÇ»ç ÀÎÅÚ¸®Àü½º, ±×¸®°í ÀÇ·á ¹®Á¦, µðÁöÅÐ Çコ, ¿µ¾÷ ¹× ¸¶ÄÉÆÃ, ½ÃÀå Á¢±Ù ¹× ±âŸ ºÐ¾ßÀÇ À̽´¿¡ ´ëÇÑ ¾÷°è Àü¹®°¡µéÀÇ °ßÇØ¸¦ Á¦°øÇÏ´Â ÀÌ º¸°í¼­´Â º¸´Ù ½º¸¶Æ®ÇÏ°í µ¥ÀÌÅÍ¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ³»¸®°í ±Þº¯ÇÏ´Â ¾÷°è¿¡¼­ °æÀï·ÂÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù.

This report examines the performance and reputation of Medical Affairs teams supporting psoriatic arthritis therapies, based on quantitative feedback from US rheumatologists. It explores how physicians interact with Medical Affairs professionals, the services they find most valuable, and how satisfied they are with current support by product. The report also highlights preferred channels and frequency of engagement, areas where physician needs are unmet, and how individual teams compare to competitors in key performance areas.

Key Questions Answered:

  • How frequently do physicians interact with Medical Affairs teams, and is the frequency of this interaction increasing or decreasing?
  • In what ways do physicians currently use the services provided by Medical Affairs teams?
  • What aspects of Medical Affairs support are most important to physicians and how satisfied are they with the support provided?
  • What are the preferred mediums for interactions between physicians and Medical Affairs teams and what is the preferred frequency of these interactions?
  • How successful are Medical Affairs teams at meeting physician needs?
  • Are Medical Affairs teams falling short or exceeding goals with any particular brands?
  • How can Medical Affairs services be improved to better meet the needs of physicians in the future?
  • In what areas are your competitors' Medical Affairs teams weakest and strongest?

Key Brands:

  • Bimzelx (bimekizumab)
  • Cimzia (certolizumab pegol)
  • Enbrel (etanercept)
  • Cosentyx (secukinumab)
  • Humira (adalimumab)
  • Remicade (infliximab)
  • Rinvoq (upadacitinib)
  • Simponi (golimumab)
  • Skyrizi (risankizumab)
  • Tremfya (guselkumab)
  • Stelara (ustekinumab)
  • Taltz (ixekizumab)
  • Xeljanz (tofacitinib)

Methodology:

FirstView reports are developed from quantitative surveys conducted with physicians selected through LiMATM, the world's largest physician directory, containing over 3 million vetted and verified physicians. Each physician is carefully chosen based on strict screening criteria to ensure the insights gathered are both relevant and reliable, reflecting the true sentiments and experiences of leading medical professionals. The findings are presented in a series of easy-to-interpret charts, enabling you to quickly grasp and analyze the data. By leveraging the vast reach and precision of LiMATM, FirstView Reports provide unparalleled, data-driven insights to guide your strategic planning and help you stay ahead in a fast-evolving healthcare landscape.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.

»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦